Zura Bio Limited filed a Form 8-K on November 9, 2026, disclosing a clinical update on its Phase 2 TibuSHIELD study of tibulizumab (ZB-106) in adults with moderate-to-severe hidradenitis suppurativa.
Aura Biosciences, Inc. filed a Current Report on Form 8-K with the SEC on November 9, 2026, announcing its financial results for the quarter ended September 30, 2026, and an updated corporate presentation.
Affiliated Managers Group, Inc. filed a Form 8-K on November 9, 2026, disclosing its financial and operating results for the quarter ended September 30, 2026, and announcing a quarterly common stock dividend of $0.01 per share.
Akamai Technologies, Inc. filed an 8-K on November 9, 2026, disclosing a November 5, 2026 amendment to its Credit Agreement and announcing an intended private offering of $2.2 billion in Convertible Senior Notes.
Scott C. Sherman, SVP, CLO and CHRO of Sally Beauty Holdings, Inc., filed a Form 4 on November 9, 2026, disclosing five derivative security acquisitions dated November 4, 2026, covering newly awarded restricted stock units and certified performance stock units.
Keurig Dr Pepper Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 9, 2026, reporting third-quarter net sales of $7,344 million and net income attributable to KDP of $882 million.
A Form 4 filed with the SEC on November 9, 2026, discloses that Mark Gregory Spinks, President of Beauty Systems Group at Sally Beauty Holdings, Inc. (NYSE:SBH), acquired five tranches of restricted stock units and performance stock units on November 4, 2026.
Brady Corporation filed a Form 8-K on November 9, 2026, disclosing the retirement notice of director Patrick W. Allender and the election of two new directors, Scott J. Robinson and Kenneth J. Spangler, effective November 9, 2026.
Foghorn Therapeutics Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 9, 2026, disclosing a sharp rise in collaboration revenue and a reduction in accumulated deficit compared to year-end 2025.
Tango Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 9, 2026, disclosing financial and operational information for the third quarter of fiscal year 2026.